JP5371746B2 - フェノール性オピオイドの制御放出 - Google Patents

フェノール性オピオイドの制御放出 Download PDF

Info

Publication number
JP5371746B2
JP5371746B2 JP2009512310A JP2009512310A JP5371746B2 JP 5371746 B2 JP5371746 B2 JP 5371746B2 JP 2009512310 A JP2009512310 A JP 2009512310A JP 2009512310 A JP2009512310 A JP 2009512310A JP 5371746 B2 JP5371746 B2 JP 5371746B2
Authority
JP
Japan
Prior art keywords
compound
substituted
group
hydrogen
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009512310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538348A (ja
JP2009538348A5 (OSRAM
Inventor
トーマス イー． ジェンキンス，
アレクサンドル コレスニコフ，
Original Assignee
ファーマコフォア， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマコフォア， インコーポレイテッド filed Critical ファーマコフォア， インコーポレイテッド
Publication of JP2009538348A publication Critical patent/JP2009538348A/ja
Publication of JP2009538348A5 publication Critical patent/JP2009538348A5/ja
Application granted granted Critical
Publication of JP5371746B2 publication Critical patent/JP5371746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009512310A 2006-05-26 2007-05-24 フェノール性オピオイドの制御放出 Active JP5371746B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80908206P 2006-05-26 2006-05-26
US60/809,082 2006-05-26
US90179507P 2007-02-16 2007-02-16
US60/901,795 2007-02-16
PCT/US2007/069683 WO2007140272A2 (en) 2006-05-26 2007-05-24 Controlled release of phenolic opioids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013160111A Division JP2013224329A (ja) 2006-05-26 2013-08-01 フェノール性オピオイドの制御放出

Publications (3)

Publication Number Publication Date
JP2009538348A JP2009538348A (ja) 2009-11-05
JP2009538348A5 JP2009538348A5 (OSRAM) 2010-07-08
JP5371746B2 true JP5371746B2 (ja) 2013-12-18

Family

ID=38645732

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009512310A Active JP5371746B2 (ja) 2006-05-26 2007-05-24 フェノール性オピオイドの制御放出
JP2013160111A Withdrawn JP2013224329A (ja) 2006-05-26 2013-08-01 フェノール性オピオイドの制御放出
JP2015022888A Withdrawn JP2015096554A (ja) 2006-05-26 2015-02-09 フェノール性オピオイドの制御放出

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013160111A Withdrawn JP2013224329A (ja) 2006-05-26 2013-08-01 フェノール性オピオイドの制御放出
JP2015022888A Withdrawn JP2015096554A (ja) 2006-05-26 2015-02-09 フェノール性オピオイドの制御放出

Country Status (14)

Country Link
US (3) US8217005B2 (OSRAM)
EP (2) EP2402037B8 (OSRAM)
JP (3) JP5371746B2 (OSRAM)
KR (1) KR20090031519A (OSRAM)
AU (1) AU2007267510B2 (OSRAM)
BR (1) BRPI0712819B8 (OSRAM)
CA (1) CA2653741C (OSRAM)
DK (1) DK2046393T3 (OSRAM)
ES (1) ES2456674T3 (OSRAM)
IL (1) IL195360A (OSRAM)
MX (1) MX2008014794A (OSRAM)
RU (1) RU2469038C2 (OSRAM)
SG (1) SG172633A1 (OSRAM)
WO (1) WO2007140272A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013224329A (ja) * 2006-05-26 2013-10-31 Pharmacofore Inc フェノール性オピオイドの制御放出

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008101202A1 (en) * 2007-02-16 2008-08-21 Pharmacofore, Inc. N-17-alkylated prodrugs of opioids
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US9023860B2 (en) 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
US20090186832A1 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid peptide pro-drugs of phenolic analgesics and uses thereof
AU2009292631A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
US8802681B2 (en) * 2008-10-17 2014-08-12 Signature Therapeutics, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
US20100227921A1 (en) * 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
AU2010231126A1 (en) * 2009-04-02 2011-10-13 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
WO2011008636A1 (en) * 2009-07-15 2011-01-20 Mallinckrodt Inc. 3-oxy-hydromorphone derivatives
JP2013503862A (ja) * 2009-09-08 2013-02-04 シグネーチャー セラピューティクス，インク． 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
US20110077222A1 (en) * 2009-09-30 2011-03-31 Mallinckrodt Inc. Sustained-Release Opiate and Opiate Derivative Compositions
WO2011083304A1 (en) * 2010-01-05 2011-07-14 Shire Llc Prodrugs of opioids and uses thereof
BR112012026768A2 (pt) * 2010-04-21 2015-09-29 Signature Therapeutics Inc composições compreendendo pró-farmacos de opioides cliváveis de modo enzimático e seus inibidores.
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20110262359A1 (en) * 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
WO2011133151A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable phenol-modified opioid prodrugs and inhibitors thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US9238020B2 (en) * 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
WO2012096887A2 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012096886A1 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
US8685916B2 (en) 2011-03-09 2014-04-01 Signature Therapeutics, Inc. Opioid prodrugs with heterocyclic linkers
BR112013022946A2 (pt) * 2011-03-09 2017-07-18 Signature Therapeutics Inc pró-fármacos de agentes ativos com ligantes heterocíclocos
CN102920995B (zh) * 2011-08-10 2015-08-26 辽宁药联制药有限公司 一种治疗肝损伤的药物组合物
WO2013093931A2 (en) 2011-09-19 2013-06-27 Sun Pharma Advanced Research Company Ltd. Novel prodrugs of phenolic drugs
US9605296B2 (en) 2011-09-29 2017-03-28 Ecole Normale Superieure De Lyon Fluorogenic peptidase substrate
CN104136031B (zh) 2011-10-26 2016-05-04 凯姆制药公司 氢吗啡酮的苯甲酸缀合物、苯甲酸衍生物缀合物和杂芳基羧酸缀合物、其前药、制备和使用方法
JP6270547B2 (ja) * 2014-03-04 2018-01-31 公益財団法人微生物化学研究会 新規生物活性物質
US10314839B2 (en) 2014-10-20 2019-06-11 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
WO2016086113A1 (en) 2014-11-25 2016-06-02 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
RU2683274C2 (ru) * 2014-12-02 2019-03-27 Кемфарм, Инк. Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты и оксиморфона, их пролекарства, способы получения и применение
AU2016332071B2 (en) * 2015-10-01 2019-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
JP2019516773A (ja) 2016-05-25 2019-06-20 コンセントリック アナルジジックス，インク． 改善された局所麻酔のための局所麻酔薬及び血管収縮薬と組み合わせたフェノールｔｒｐｖ１アゴニストのプロドラッグ
AU2018234911B2 (en) 2017-03-17 2024-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
EP3686182A4 (en) * 2017-09-22 2021-06-09 Sumitomo Dainippon Pharma Co., Ltd. CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
TW202019887A (zh) 2018-07-27 2020-06-01 美商同心止痛劑股份有限公司 酚系trpv1促效劑之聚乙二醇化前藥
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.
US11957676B1 (en) * 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3927036A (en) * 1972-05-25 1975-12-16 Abbott Lab Basic carbonates and carbamates of benzopyrans
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4820523A (en) 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4816263A (en) 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
DK0814861T3 (da) 1995-03-14 2002-10-07 Siemens Ag Udskiftelig præcisionsdoseringsenhed til ultralydforstøveranordning
EP0814860B1 (en) 1995-03-14 1999-11-03 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
FR2779651B1 (fr) 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
JP2002540073A (ja) * 1999-03-10 2002-11-26 ロータス バイオケミカル コーポレイション 化学化合物の保護および放出のためのタンパク質コンホメーションの使用
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
JP2004523480A (ja) * 2000-08-22 2004-08-05 ニュー リバー ファーマシューティカルズ， インコーポレイテッド 活性作用物質送達系ならびに活性作用物質の保護および投与方法
SI1436012T1 (en) 2001-10-18 2018-03-30 Nektar Therapeutics Polymer conjugates of opioid antagonists
AU2002351388A1 (en) 2001-12-14 2003-06-30 The University Of Wyoming Methods and compositions for controlled release of drugs
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
IL163667A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
US20040086551A1 (en) 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
ES2371462T3 (es) * 2003-01-13 2012-01-03 Shire Llc Conjugados de carbohidratos para prevenir el abuso de sustancias controladas.
ATE454169T1 (de) 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
US8524272B2 (en) 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
NZ546226A (en) * 2003-09-30 2009-03-31 Shire Llc Oxycodone conjugates for prevention of overdose or abuse
US7241807B2 (en) 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
WO2007022535A2 (en) * 2005-08-19 2007-02-22 Pharmacofore, Inc. Prodrugs of active agents
SG172633A1 (en) * 2006-05-26 2011-07-28 Pharmacofore Inc Controlled release of phenolic opioids
US20080207668A1 (en) * 2006-10-06 2008-08-28 New River Pharmaceuticals Inc. Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse
US20090005444A1 (en) 2007-06-21 2009-01-01 Xenoport, Inc. Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
WO2009036322A1 (en) 2007-09-14 2009-03-19 Xenoport, Inc. Use of propofol prodrugs for treating neuropathic pain

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013224329A (ja) * 2006-05-26 2013-10-31 Pharmacofore Inc フェノール性オピオイドの制御放出

Also Published As

Publication number Publication date
EP2046393A2 (en) 2009-04-15
WO2007140272A3 (en) 2008-02-14
JP2015096554A (ja) 2015-05-21
ES2456674T3 (es) 2014-04-23
US20150148284A1 (en) 2015-05-28
SG172633A1 (en) 2011-07-28
US20100035826A1 (en) 2010-02-11
WO2007140272A2 (en) 2007-12-06
BRPI0712819A2 (pt) 2013-03-26
IL195360A0 (en) 2009-08-03
DK2046393T3 (da) 2014-05-12
IL195360A (en) 2015-05-31
US20120270894A1 (en) 2012-10-25
EP2402037A1 (en) 2012-01-04
EP2046393B1 (en) 2014-02-12
CA2653741C (en) 2015-07-07
RU2469038C2 (ru) 2012-12-10
JP2009538348A (ja) 2009-11-05
BRPI0712819B1 (pt) 2021-04-06
BRPI0712819B8 (pt) 2021-05-25
MX2008014794A (es) 2009-04-08
HK1127901A1 (en) 2009-10-09
KR20090031519A (ko) 2009-03-26
US8921418B2 (en) 2014-12-30
AU2007267510A1 (en) 2007-12-06
EP2402037B1 (en) 2019-10-23
EP2402037B8 (en) 2019-12-04
AU2007267510B2 (en) 2013-01-31
RU2008151690A (ru) 2010-07-10
US8217005B2 (en) 2012-07-10
CA2653741A1 (en) 2007-12-06
JP2013224329A (ja) 2013-10-31

Similar Documents

Publication Publication Date Title
JP5371746B2 (ja) フェノール性オピオイドの制御放出
US8163701B2 (en) Prodrugs of active agents
US20120142718A1 (en) N-17-Alkylated Prodrugs of Opioids
JP5107576B2 (ja) Ｇａｂａ類似体のプロドラッグを使用する不穏下肢症候群の治療または予防
US20110105381A2 (en) Prodrugs of Peripheral Phenolic Opioid Antagonists
MXPA03011566A (es) Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
KR20060119971A (ko) Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
AU2004227995B2 (en) Treating or preventing hot flashes using prodrugs of GABA analogs
CN101528264B (zh) 酚类阿片样物质的受控释放
US20070049626A1 (en) Treating premature ejaculation using gabapentin and pregabalin prodrugs
AU2013202270B2 (en) Controlled release of phenolic opioids
HK1165314A (en) Controlled release of phenolic opioids
HK1127901B (en) Controlled release of phenolic opioids
HK1165314B (en) Controlled release of phenolic opioids
CN1791398B (zh) 用gaba类似物的前药治疗或预防潮热

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130917

R150 Certificate of patent or registration of utility model

Ref document number: 5371746

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250